Regulatory T cells: Hypes and limitations

Current Opinion in Organ Transplantation

Volumn 13, Issue 4, 2008, Pages 333-338

  Schiopu, Alexandru ^a   Wood, Kathryn J ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Antigen specific; CD127; Clinical trials; Forkhead box P3; Interleukin 35; Operational tolerance; Rapamycin; Regulatory T cells; Tr1

Indexed keywords

CYCLOSPORIN; RAPAMYCIN;

CELL FUNCTION; CELL THERAPY; DRUG MECHANISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NATURAL KILLER CELL; NONHUMAN; ORGAN TRANSPLANTATION; PATIENT SAFETY; REGULATORY T LYMPHOCYTE; REVIEW;

ADOPTIVE TRANSFER; ANIMALS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 61649096596     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283061137     Document Type: Review

References (45)

1. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151 -1164.
2. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3:199-210.
3. Gavin MA, Rasmussen JP, Fontenot JD, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007; 445:771-775.
4. Lin W, Haribhai D, Relland LM, et al. Regulatory T cell development in the absence of functional Foxp3. Nat Immunol 2007; 8:359-368.
5. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007; 8:277-284.
6. Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13:1299-1307.
7. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007; 445:766-770.
8. Yong Z, Chang L, Mei YX, Yi L Role and mechanisms of CD4+CD25+ regulatory T cells in the induction and maintenance of transplantation tolerance. Transpl Immunol 2007; 17:120-129.
9. Chikuma S, Bluestone JA. Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative disease. EurJ Immunol 2007; 37:1285-1289.
10. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005; 6:338-344.
11. Vu MD, Xiao X, Gao W, et al. OX40 costimulation turns off Foxp3+ Tregs. Blood 2007; 110:2501 -2510.
12. Bushell A, Wood K. GITR ligation blocks allograft protection by induced CD25+CD4+ regulatory T cells without enhancing effector T-cell function. Am J Transplant 2007; 7:759-768.
13. Thebault P, Condamine T, Heslan M, et al. Role of IFNgamma in allograft tolerance mediated by CD4+CD25+ regulatory T cells by induction of IDO in endothelial cells. Am J Transplant 2007; 7:2472-2482.
14. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450:566-569.
15. Long E, Wood KJ. Understanding FOXP3: progress towards achieving transplantation tolerance. Transplantation 2007; 84:459-461.
16. Kang SM, Tang Q, Bluestone JA. CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant 2007; 7: 1457-1463.
17. Battaglia M, Stabilini A, Draghici E, et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 2006; 55:40-49.
18. Verbsky JW. Therapeutic use of T regulatory cells. Curr Opin Rheumatol 2007; 19:252-258.
19. Zhang D, Yang W, Degauque N, et al. New differentiation pathway for double-negative regulatory T cells that regulates the magnitude of immune responses. Blood 2007; 109:4071-4079.
20. Martinez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7:309-319.
21. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007; 7:585-598.
22. Golshayan D, Jiang S, Tsang J, et al. In vitro-expanded donor alloantigenspecific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 2007; 109:827-835.
23. Jiang S, Tsang J, Game DS, et al. Generation and expansion of human CD4+ CD25+ regulatory T cells with indirect allospecificity: potential reagents to promote donor-specific transplantation tolerance. Transplantation 2006; 82:1738-1743.
24. Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008; 4:88-92.
25. Alexander SI, Smith N, Hu M, et al. Chimerismand tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med 2008; 358:369-374.
26. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358:353-361.
27. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358:362-368.
28. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3and suppressive function of human CD4+Treg cells. J Exp Med 2006; 203:1701 -1711.
29. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203:1693-1700.
30. Hoffmann P, Eder R, Boeld TJ, et al. Only the CD45RA+ subpopulation of CD4+CD25 high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 2006; 108:4260-4267.
31. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-742.
32. Zeller JC, Panoskaltsis-Mortari A, Murphy WJ, et al. Induction of CD4+T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol 1999; 163:3684-3691.
33. Warnecke G, Bushell A, Nadig SN, Wood KJ. Regulation of transplant arteriosclerosis by CD25+CD4+ T cells generated to alloantigen in vivo. Transplantation 2007; 83:1459-1465.
34. Salama AD, Womer KL, Sayegh MH. Clinical transplantation tolerance: many rivers to cross. J Immunol 2007; 178:541 9-5423.
35. Demirkiran A, Baan CC, Kok A, et al. Intrahepatic detection of FOXP3 gene expression after liver transplantation using minimally invasive aspiration biopsy. Transplantation 2007; 83:819-823.
36. Bestard O, Cruzado JM, Mestre M, et al. Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007; 179:4901 -4909.
37. Adams AB, Pearson TC, Larsen CP. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev 2003; 196:147-160.
38. Yang J, Brook MO, Carvalho-Gaspar M, et al. Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci USA 2007; 104:19954-19959.
39. Zeiser R, Leveson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008; 111:453-462.
40. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med 2008; 205:565-574.
41. Battaglia M, Stabilini A, MigliavaccaB, et al. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177:8338-8347.
42. Turnquist HR, Raimondi G, Zahorchak AF, et al. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178:7018-7031.
43. Ruggenenti P, Perico N, Gotti E, et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 2007; 84:956-964.
44. Noris M, Casiraghi F, Todeschini M, et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007; 18:1007-1018.
45. San Segundo D, Fabrega E, Lopez-Hoyos M, Pons F. Reduced numbers of blood natural regulatory T cells in stable liver transplant recipients with high levels of calcineurin inhibitors. Transplant Proc 2007; 39:2290-2292.